Skip to main content

Table 2 CCND3 rs2479717 genotype frequency across stage, grade, and estrogen receptor status

From: Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort

 

CCND3 rs2479717 genotype

 

AA

AT

TT

Missing

Stage

    

   1

1,193 (54.5%)

808 (36.9%)

142 (6.5%)

48 (2.2%)

   2

1,031 (52.0%)

753 (38.0%)

145 (7.3%)

54 (2.7%)

   3 or 4

90 (46.4%)

82 (42.3%)

17 (8.8%)

5 (2.6%)

   Missing

60 (58.8%)

31 (30.4%)

9 (8.8%)

2 (2.0%)

Grade

    

   1

484 (55.4%)

314 (35.9%)

60 (6.9%)

16 (1.8%)

   2

889 (52.7%)

658 (39.0%)

104 (6.2%)

36 (2.1%)

   3

533 (52.3%)

375 (36.8%)

86 (8.4%)

26 (2.5%)

   Missing

468 (52.5%)

327 (36.7%)

63 (7.1%)

34 (3.8%)

Estrogen receptor status

    

   Positive

1,089 (55.1%)

717 (36.3%)

130 (6.6%)

39 (2.0%)

   Negative

320 (49.3%)

262 (40.4%)

53 (8.2%)

14 (2.2%)

   Missing

965 (52.3%)

695 (37.6%)

130 (7.0%)

56 (3.0%)